Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
RAC
vs
S
S&P/ASX 300
RAC
Over the past 12 months, RAC has underperformed S&P/ASX 300, delivering a return of -52% compared to S&P/ASX 300's 3% drop.
Stocks Performance
RAC vs S&P/ASX 300
Performance Gap
RAC vs S&P/ASX 300
Performance By Year
RAC vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Racura Oncology Ltd
Glance View
Race Oncology is an Australian biotechnology company that is trying to turn an old cancer drug, bisantrene, into a modern treatment. Its main work is research, lab testing, and clinical development of drug candidates for cancers such as acute myeloid leukemia and other hard-to-treat blood cancers. The company is not a mass-market drug maker; it is a development-stage biotech that is building evidence for its own medicine candidates and related intellectual property. Because it is still developing its products, Race Oncology does not sell a broad range of medicines to end patients. Instead, its money comes mainly from research and development activity, which can include licensing its drug rights, partnering with larger drug companies, and eventually selling an approved therapy if one reaches the market. Its main customers, in the long run, would be hospitals, cancer specialists, and patients treated through the healthcare system. What makes its business model different is that it is focused on repurposing and improving a known compound rather than starting from scratch with a brand-new molecule. That can give the company a clearer scientific path than many early biotech peers, because it can build on existing knowledge about the drug while trying to find a new use in oncology. In the drug value chain, Race Oncology sits at the research-and-development stage, where the goal is to create clinical proof that can support a future product or licensing deal.
